CRDF

Cardiff Oncology Inc

Add to Watchlist

Advanced Chart

2.320

+0.06(2.655%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

2.3854

Open

2.260

VWAP

2.33

Vol

1.02M

Mkt Cap

154.34M

Low

2.260

Amount

2.38M

EV/EBITDA(TTM)

Total Shares

44.74M

79.39M

EV/OCF(TTM)

P/S(TTM)

242.72

Cardiff Oncology, Inc. is a clinical-stage biotechnology company. It is leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with unmet medical need. It is focused on clinical programs in indications, such as RAS-mutated metastatic colorectal cancer (mCRC), and in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), and triple negative breast cancer (TNBC). Its lead drug candidate, Onvansertib, is an oral, small-molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life. It has other ongoing and planned clinical trials of onvansertib: one trial (CRDF-004) in first-line treatment in patients with RAS-mutated mCRC, and investigator-initiated trials in first-line mPDAC, relapsed SCLC and unresectable locally advanced or metastatic TNBC.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

80.00K

-26.61%

121.43K

-19.58%

121.43K

-26.41%

Estimates Revision

The market is revising Upward the revenue expectations for Cardiff Oncology, Inc. (CRDF) for FY2025, with the revenue forecasts being adjusted by 9.74% over the past three months. During the same period, the stock price has changed by -23.43%.

Revenue Estimates for FY2025

Revise Upward

+9.74%

In Past 3 Month

Stock Price

Go Down

-23.43%

In Past 3 Month

7 Analyst Rating

Wall Street analysts forecast CRDF stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRDF is 12.63 USD with a low forecast of 3.50 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

1 Hold

0 Sell

Strong Buy

Current: 2.320

Low

3.50

Averages

12.63

High

19.00

Current: 2.320

Low

3.50

Averages

12.63

High

19.00

H.C. Wainwright

Buy

downgrade

$18 -> $10

2025-08-06

Reason

H.C. Wainwright

Price Target

$18 -> $10

2025-08-06

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Cardiff Oncology to $10 from $18 and keeps a Buy rating on the shares following the Q2 report. The firm reduced its probability of approval for onvansertib to 25% from 40%, seeing a higher risk profile following the most recent data.

Ladenburg

Kevin Degeeter

Buy

initiated

$19

2025-07-08

Reason

Ladenburg

Kevin Degeeter

Price Target

$19

2025-07-08

initiated

Buy

Reason

Ladenburg analyst Kevin Degeeter initiated coverage of Cardiff Oncology with a Buy rating and $19 price target. The firm, which sees potential for onvansertib to become a new treatment option for first-line KRAS and NRAS mutated colorectal cancer, expects a planned update on July 29 to clarify the tolerability profile and potentially enable selection of an onvansertib dose for Phase 3 development.

Jefferies

Hold

initiated

$3.50

2025-06-24

Reason

Jefferies

Price Target

$3.50

2025-06-24

initiated

Hold

Reason

Jefferies initiated coverage of Cardiff Oncology with a Hold rating and $3.50 price target. The company's onvansertib has shown promising early data in 1L RAS mutations metastatic colorectal cancer, but the data are early and the drug's mechanism of action is risky with prior failed studies, the analyst tells investors in a research note. The firm believes catalysts for rest of year may not provide adequate efficacy insight. It plans to reassess the Hold rating post the July 29 data update.

H.C. Wainwright

Buy

maintain

$18

2025-06-19

Reason

H.C. Wainwright

Price Target

$18

2025-06-19

maintain

Buy

Reason

H.C. Wainwright says the "market overreaction" in shares of Cardiff Oncology "provides an attractive stock price entry point." Cardiff announced that it will now share updated clinical data from the CRDF-004 trial on July 29, as opposed to the prior guidance of the first half of 2025, driving an after-hours selloff of 13%, the analyst tells investors in a research note. H.C. Wainwright notes that during its discussion with management yesterday, the company disclosed the rationale for this slight delay is that the majority of the enrolled patients shall have at least two post-baseline scans by this time point. "This is a prudent and investor-conscious decision since it provides a more robust dataset and potentially removes the concern of unconfirmed responses," the firm contends. It reiterates a Buy rating on the shares with an $18 price target.

H.C. Wainwright

Robert Burns

Buy

upgrade

$17 -> $18

2025-05-09

Reason

H.C. Wainwright

Robert Burns

Price Target

$17 -> $18

2025-05-09

upgrade

Buy

Reason

H.C. Wainwright analyst Robert Burns raised the firm's price target on Cardiff Oncology to $18 from $17 and keeps a Buy rating on the shares following the Q1 report.

HC Wainwright & Co.

Robert Burns

Strong Buy

Maintains

$13 → $17

2025-02-28

Reason

HC Wainwright & Co.

Robert Burns

Price Target

$13 → $17

2025-02-28

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Cardiff Oncology Inc (CRDF.O) is -2.69, compared to its 5-year average forward P/E of -5.79. For a more detailed relative valuation and DCF analysis to assess Cardiff Oncology Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-5.79

Current PE

-2.69

Overvalued PE

0.92

Undervalued PE

-12.49

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

808.47

Current PS

376.47

Overvalued PS

1549.51

Undervalued PS

67.43